Matinas BioPharma Holdings, Inc. (MTNB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US5768103039
Matinas BioPharma Holdings, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -6.96 m USD |
| EBIT | -10.35 m USD |
| Net income | -10.35 m USD |
| Diluted EPS – continuing operations | -2.00 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
More stocks
- CEMTREX INC (CETX)
- Bravo Multinational Inc. (BRVO)
- OLENOX INDUSTRIES INC. (OLOX)
- Fortune Valley Treasures, Inc. (FVTI)
- Nexentis Technologies Inc. (NXTS)
- Presidio Property Trust, Inc. (SQFT)
- Cybin Inc (HELP.NE)
- HEALTHY CHOICE WELLNESS CORP. (HCWC)
- ORAGENICS INC (OGEN)
- Kaya Holdings, Inc. (KAYS)
- Adagio Medical Holdings, Inc. (ADGM)
- GPO Plus, Inc. (GPOX)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.